IL-33 Antibody (1061A) [Unconjugated]

IL-33 was detected in immersion fixed paraffin-embedded sections of human tonsil using Rabbit Anti-Human IL-33 Monoclonal Antibody (Catalog # MAB36252) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Rabbit HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS005) and counterstained with hematoxylin (blue). Specific staining was localized to nuclei in high endothelial venules. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

• Reactivity: Hu
• Applications: IHC
• Clone: 1061A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

IL-33 Antibody (1061A) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: E. coli-derived recombinant human IL-33
  Ser112-Thr270
  Accession # O95760
• Specificity: Detects human IL-33 in direct ELISAs.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Gene: IL33
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 10-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: Sodium Azide
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-33 Antibody (1061A) [Unconjugated]

• C9orf26
• C9orf26chromosome 9 open reading frame 26 (NF-HEV)
• DKFZp586H0523
• DVS27
• DVS27-related protein
• IL1F11
• IL-1F11
• IL33
• IL-33
• interleukin 33
• Interleukin-1 family member 11
• interleukin-33
• NFHEV
• NF-HEV
• NF-HEVNFEHEV
• Nuclear factor from high endothelial venules
• RP11-575C20.2

Background

IL-33, also known as NF-HEV and DVS 27, is a 30 kDa proinflammatory protein that may also regulate gene transcription (1‑3). DVS 27 was identifed as a gene that is up‑regulated in vasospastic cerebral arteries (1). NF-HEV was described as a nuclear factor that is preferentially expressed in the endothelial cells of high endothelial venules relative to endothelial cells from other tissues (2). IL-33 was identified based on sequence and structural homology with IL-1 family cytokines (3). DVS 27, NF-HEV, and IL-33 share 100% amino acid sequence identity. IL-33 is constitutively expressed in smooth muscle and airway epithelia. It is up‑regulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL-1 alpha or IL-1 beta stimulation (1, 3). Similar to IL-1, IL-33 can be cleaved in vitro by caspase-1, generating an N-terminal fragment that is slightly shorter than the C-terminal fragment (3, 4). The N-terminal portion of full length IL-33 contains a predicted bipartite nuclear localization sequence and a homeodomain-like helix-turn-helix DNA binding domain. By immunofluorescence, full length IL-33 localizes to the nucleus in HUVECs and transfectants (2). The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling through mast cell IL-1 R4/ST2L, a longtime orphan receptor involved in the augmentation of Th2 cell responses (3, 5-7). A ternary signaling complex is formed by the subsequent association of IL-33 and ST2L with IL-1R AcP (8). Stimulation of Th2 polarized lymphocytes with mature IL-33 in vitro induces IL-5 and IL-13 secretion (3). In vivo administration of mature IL-33 promotes increased production of IL-5, IL-13, IgE, and IgA, as well as splenomegaly and inflammatory infiltration of mucosal tissues (3). Full length and mature human IL-33 share 52‑58% aa sequence identity with mouse and rat IL-33. Human IL-33 shares less than 20% aa sequence identity with other IL-1 family proteins.

1. Onda, H. et al. (1999) J. Cereb. Blood Flow Metab. 19:1279.
2. Baekkevold, E.S. et al. (2003) Am. J. Pathol. 163:69.
3. Schmitz, J. et al. (2005) Immunity 23:479.
4. Black, R.A. et al. (1989) J. Biol. Chem. 264:5323.
5. Xu, D. et al. (1998) J. Exp. Med. 187:787.
6. Lohning, M. et al. (1998) Proc. Natl. Acad. Sci. USA 95:6930.
7. Dinarello, C.A. (2005) Immunity 23:461.
8. Chackerian, A.A. et al. (2007) J. Immunol. 179:2551.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-33 Antibody (MAB36252)(3)

Publications using MAB36252

• ?J Adamski, A Starzy?ska, P Adamska, M Kunc, M Sakowicz-B, G Marvaso, D Alterio, A Korwat, BA Jereczek-F, R P?ksa High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments Biomedicines, 2021-09-01;9(9):. 2021-09-01 [PMID: 34572318] (IHC, Human)
• P Aparicio-D, H Cannelle, MB Buechler, S Nguyen, SM Kallert, S Favre, N Alouche, N Papazian, B Ludewig, T Cupedo, DD Pinschewer, SJ Turley, SA Luther Fibroblast-derived IL-33 is dispensable for lymph node homeostasis but critical for CD8 T cell responses to acute and chronic viral infection Eur. J. Immunol., 2020-08-05;0(0):. 2020-08-05 [PMID: 32700362] (IHC, Mouse)
• M Wagner, KN Ealey, H Tetsu, T Kiniwa, Y Motomura, K Moro, S Koyasu Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s Cell Rep, 2020-02-25;30(8):2743-2757.e5. 2020-02-25 [PMID: 32101749] (IHC, Human)

Bioinformatics

• Gene Symbol: IL33
• Uniprot:
  • O95760()